Follow us on:

Linkedin Facebook

Argent BioPharma Positive Quarter Activity Report with CEO Roby Zomer (VIDEO)

Argent BioPharma Ltd (ASX:RGT) Managing Director and CEO of Argent BioPharma Roby Zomer joins DirectorsTalk Interviews to discuss its Quarter Activity Report published to the market.

In this interview Roby explains why a comprehensive restructuring process was undertaken and what is different, how the company product portfolio is performing, the addition of Dr. Shlomo Sadoun to the advisory board and how Roby sees the outlook for Argent BioPharma.

Argent BioPharma Ltd, is an Australia-based drug discovery company focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies.

Find more news, interviews, share price & company profile here for:

    Share this interview

    Twitter
    LinkedIn
    Facebook
    Email
    WhatsApp
    Argent BioPharma Positive Quarter Activity Report with CEO Roby Zomer (VIDEO)

    Other Interviews

    More News

    Search

    Useful links

    Disclaimer

    You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

    © 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.